The Effect of Nasal Carbon Dioxide (CO2) in the Treatment of Seasonal Allergic Rhinitis - Full Text View

Purpose

The purpose of this study is to evaluate the safety and effect of nasal carbon dioxide in the treatment of Seasonal Allergic Rhinitis

Condition	Intervention	Phase
Seasonal Allergic Rhinitis	Drug: Nasal CO2 Drug: Placebo	Phase 2


Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Blind (Participant, Investigator) Primary Purpose: Treatment
Official Title:	A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of Nasal Carbon Dioxide in the Treatment of Seasonal Allergic Rhinitis

Resource links provided by NLM:

MedlinePlus related topics: Hay Fever

Drug Information available for: Carbon dioxide

U.S. FDA Resources

Further study details as provided by Capnia, Inc.:

Primary Outcome Measures:

The mean change in reflective Total Nasal Symptom Score (TNSS) over the Treatment Period compared to baseline in nasal CO2 or placebo [ Time Frame: 14 days ]


Enrollment:	453
Study Start Date:	July 2008
Study Completion Date:	November 2008
Primary Completion Date:	October 2008 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: Active CO2 Gas	Drug: Nasal CO2 Twice daily during the 14 day Treatment Period
Placebo Comparator: Placebo Inactive Placebo Gas	Drug: Placebo Use of the study drug dispenser at the same frequency as the active arm

Detailed Description:

This multi-center, randomized, double-blind, placebo-controlled, parallel group trial will evaluate the efficacy and safety of a nasal, non-inhaled administration of carbon dioxide (CO2) in patients with seasonal allergic rhinitis. An estimated 500 patients who meet the eligibility criteria will be enrolled into this study at approximately 25 sites to ensure that approximately 400 patients are randomized and complete the study.

Eligibility


Ages Eligible for Study:	18 Years to 65 Years (Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Able to read and understand informed consent and voluntarily consent to sign the informed consent form
Able to comply with the requirements of the protocol (e.g., complete the diary within the protocol-specified window)
Minimal 2-year history of Fall seasonal allergic rhinitis requiring pharmacotherapy
Positive skin test to one or more Fall seasonal allergen (e.g., ragweed, birch pollen, etc.)
Females of childbearing potential must commit to using an acceptable method of birth control and have a negative pregnancy test

Exclusion Criteria:

History of asthma (other than mild intermittent)
Acute or significant sinusitis or upper respiratory infection within 14 days of enrollment
Existing serious medical condition (e.g., severe emphysema) that precludes participation
Females who are pregnant or breast-feeding and/or who plan to become pregnant or to breast-feed during the study participation or within 7 days after the last study drug administration
Initiation of immunotherapy or have a change in immunotherapy dose within the 6 months preceding enrollment (if on immunotherapy, the same dose must be maintained throughout the trial)
Planned travel outside the study area for the duration of study period
Participation in another clinical study within 30 days of planned enrollment date and for the duration of the study
Participation in a previous study with Nasal CO2

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00688441

Sponsors and Collaborators

Capnia, Inc.

Investigators


Study Chair:	S. David Miller, MD	Northeast Medical Research Associates, Inc.

More Information


Responsible Party:	Kristen Yen, Associate Director, Clinical, Capnia, Inc.
ClinicalTrials.gov Identifier:	NCT00688441 History of Changes
Other Study ID Numbers:	C215
Study First Received:	May 29, 2008
Last Updated:	August 18, 2010

Keywords provided by Capnia, Inc.:


Randomized Double-Blind Multi-Center Placebo-Controlled Phase II Nasal Carbon Dioxide	Carbon Dioxide Efficacy Safety Total Nasal Symptom Score RQLQ

Additional relevant MeSH terms:


Rhinitis Rhinitis, Allergic Rhinitis, Allergic, Seasonal Nose Diseases Respiratory Tract Diseases Respiratory Tract Infections	Otorhinolaryngologic Diseases Respiratory Hypersensitivity Hypersensitivity, Immediate Hypersensitivity Immune System Diseases

ClinicalTrials.gov processed this record on May 25, 2017